Core Viewpoint - A series of collaborative innovation platforms focusing on cutting-edge technologies have recently emerged, showcasing advancements in the field of new energy smart connected vehicles, particularly in solid-state batteries and BeiDou navigation technologies [1] Group 1: Solid-State Battery Advantages - Solid-state batteries are considered the "ultimate solution" for next-generation power batteries due to their higher safety, greater energy density, longer lifespan, and faster charging speed compared to the currently prevalent lithium-ion batteries [1] - Many countries globally are accelerating their investments and developments in solid-state battery technology [1] Group 2: Industry Developments and Future Outlook - Collaborative innovation platforms involving academia, industry, and research have made breakthroughs in key material fields [1] - According to Ouyang Minggao, an academician at the Chinese Academy of Sciences, vehicle testing for solid-state batteries is expected to begin by the end of this year or next year, with large-scale production anticipated by 2027, although it is still in the demonstration verification phase [1] - Mass production of solid-state battery products is expected to be realized before 2030 [1]

本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，深圳市新产业生物医学工程股份有限公司（以下简称"公司"）收到 了广东省药品监督管理局颁发的 1 项《医疗器械注册证》。具体情况如下： | 胰岛素样生长 因子Ⅰ测定试 | Ⅱ类 | 粤械注准 | 2025 | 年 | 03 月 | 17 | 日至 | 本试剂盒用于定量测定人 血清或血浆中胰岛素样生 长因子Ⅰ（IGF-Ⅰ）的含量， | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 剂盒（磁微粒 | | 20252400419 | 2030 | 年 | 03 | 月 16 | 日 | | | 产品名称 化学发光法）注 | 注册 分类 | 注册证编号 | | | 注册证有效期 | | | 适用范围 临床上主要用于生长紊乱 的辅助诊断。 | 证券代码：300832 证券简称：新产业 公告编号：2025-014 深圳市新产业生物医学工程股份有限公司 关于获得医疗器械注册证的公告 深圳市新产业生物医学工程股份有限公司 董事会 2025 年 3 月 19 ...

证券代码：300832 证券简称：新产业 公告编号：2025-013 二、 对公司的影响及风险提示 1 截至目前，公司已先后取得 191 项化学发光试剂《医疗器械注册证》（共 272 个注册证）。以上试剂新产品医疗器械注册证的取得，丰富了公司化学发光 检测产品中"肝纤维化"项目类别，将对公司发展具有正面影响，但对近期的 生产经营和业绩不会产生重大影响，敬请投资者给予关注并注意投资风险。 深圳市新产业生物医学工程股份有限公司 关于获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，深圳市新产业生物医学工程股份有限公司（以下简称"公司"）收到 了广东省药品监督管理局颁发的 1 项《医疗器械注册证》。具体情况如下： | 产品名称 | | 注册 | 注册证编号 | | | 注册证有效期 | | | 适用范围 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 分类 | | | | | | | | | 高尔基体蛋白 | 73 | | 粤械注准 | 2025 ...

Group 1 - The Jiangsu Suhao Artificial Intelligence Application Innovation Industry Special Fund (Limited Partnership) has been established with a total investment of 1 billion yuan [1] - The fund's operational scope includes equity investment, investment activities using self-owned funds, and venture capital limited to investing in unlisted companies [1] - The fund is jointly funded by Jiangsu Suhao Holding Group Co., Ltd. and Jiangsu Strategic Emerging Industry Mother Fund Co., Ltd. among others [1]

Core Viewpoint - Nais Group's green low-carbon detergent technology has been recognized by the Ministry of Industry and Information Technology, showcasing a commitment to sustainable development through the use of over 92% natural ingredients, replacing traditional petroleum-based materials [1][2] Group 1: Green Technology and Innovation - The company has implemented a comprehensive transformation towards high-quality green low-carbon products, with over 90% of its products undergoing green upgrades [2][3] - Nais has developed a new concentrated laundry detergent with an active ingredient content of 48%, three times the national standard, enhancing environmental efficiency through reduced packaging and simplified design [2][3] - The company has established a national-level key laboratory for detergents and has been involved in drafting the first low-carbon product industry standards in the daily chemical sector [3] Group 2: Global Expansion Strategy - Nais is pursuing a dual-circulation strategy focusing on both domestic and international markets, enhancing the global influence of Chinese products [4][5] - The company has established overseas production bases, including the first factory in Angola, and is expanding its footprint in various countries, including Uganda and Egypt [5][6] - Nais is integrating global research resources to drive technological innovation in green development, collaborating with international industry leaders in various fields [6][8] Group 3: Ecological Transformation - The "Ecological Nais" initiative aims to create a new industrial system that integrates ecological research, product development, and consumer experience [7][8] - The company is focusing on developing a beautiful and healthy industry by leveraging advanced technologies and resources to enhance product offerings [8] - Nais is committed to meeting and leading high-quality consumer demands through innovative practices and new industry explorations [8]

Group 1 - Central enterprises are required to enhance the revenue share of strategic emerging industries under the premise of adapting to local conditions [1] - The State-owned Assets Supervision and Administration Commission (SASAC) plans to implement a doubling investment initiative for strategic emerging industries this year [1] - Local state-owned enterprises are also setting clear plans and goals to increase their focus on strategic emerging and future industries [1] Group 2 - The government work report emphasizes the need to develop new productive forces and modern industrial systems, with specific measures to cultivate emerging and future industries [2] - There is a strong focus on original technology development, with leading tech companies encouraged to spearhead major breakthroughs and form upgraded innovation coalitions [2] - Local governments, such as Hebei, are setting hard targets for enhancing independent innovation capabilities, including a 70% investment ratio in major research projects [2] Group 3 - Under policy guidance, "increased efforts" is a key theme for state-owned enterprises to transition towards new industries this year [3] - Heilongjiang aims for strategic emerging industries to account for over 20% of investment and revenue by the end of 2025, doubling from 2022 [3] - Gansu is focusing on developing new materials, renewable energy, and other strategic emerging industries while leveraging its unique advantages [3]

Group 1 - The central government emphasizes the need for state-owned enterprises to enhance the revenue share of strategic emerging industries while adopting various models such as self-cultivation, strategic alliances, and investment platforms [1][2] - The State-owned Assets Supervision and Administration Commission (SASAC) plans to implement a doubling investment initiative for strategic emerging industries this year, with clear targets set for both central and local state-owned enterprises [1][3] - Local governments, such as Zhejiang and Hebei, are actively working on enhancing innovation capabilities and setting specific targets for R&D investment and technology transfer rates [2][3] Group 2 - The focus on "new" industries is a key theme for state-owned enterprises this year, with provinces like Heilongjiang and Guizhou aiming for significant increases in investment and revenue from strategic emerging industries by 2025 [3] - Companies like China Aluminum Group are prioritizing the development of strategic emerging industries and future industries, with ambitious growth targets for investment and revenue in new materials and renewable energy [3]

Group 1 - The core viewpoint emphasizes the importance of developing strategic emerging industries through various methods such as independent cultivation, strategic alliances, equity cooperation, and investment platform creation [1] - There is a call to accelerate the development of future industries and actively compete in the "future arena" [1] - Chain-leading enterprises are encouraged to play a greater role in strengthening and supplementing supply chains [1]

证券代码：300832 证券简称：新产业 公告编号：2025-012 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）于近日收到 1项国家知识产权局、3项日本特许厅颁发的《发明专利证书》，现将本次取得的 发明专利具体情况公告如下： 1、发明名称：试剂组合以及免离心的全血中目标免疫抑制剂的检测方法 中国专利号：ZL202311861025.6 专利权人：深圳市新产业生物医学工程股份有限公司 发明人：饶捷、李婷华、张云、罗春、郑文迪、徐红 专利申请日：2023年12月31日 授权公告日：2025年03月07日 上述专利保护技术为公司自主研发，本发明涉及体外检测技术领域，具体涉 及在全血中检测免疫抑制剂，通过优化全血处理剂的组分并结合小分子夹心法检 测技术，实现免离心检测，且检测结果能与质谱检测结果保持高度一致，极大提 高了检测效率。 深圳市新产业生物医学工程股份有限公司 关于公司获得发明专利证书的公告 1 上述专利保护技术为公司自主研发，本发明应用于公司全自动核酸检测分析 仪器Molecision R8，涉及 ...

证券代码：300832 证券简称：新产业 公告编号：2025-011 深圳市新产业生物医学工程股份有限公司 关于控股股东部分股份办理质押及实际控制人部分股份解除质押 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）于近日收到 公司控股股东西藏新产业投资管理有限公司（以下简称"西藏新产业"）和实际 控制人翁先定先生的函告，获悉西藏新产业所持有的公司 720 万股股份办理了质 押手续；另，翁先定先生已质押给国投证券资产管理有限公司（原名：安信证券 资产管理有限公司）的其所持有的公司 790 万股股份办理了解除质押手续。具体 事项如下： 二、 公司实控人部分质押股份解除质押的基本情况 | 股东 名称 | 是否为控股股东 或第一大股东及 | 本次解除质 押股份数量 | 占其所持 股份比例 | 占公司总 股本比例 | 质押 起始日 | | 质押 解除日 | | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 其一 ...